Tumor microenvironment targeting compound for cancer therapy
ChangeBridge: EPO Bulletin - Therapeutics (A61P)
Summary
EPO published patent application EP3184540A1 for a tumor microenvironment targeting compound for cancer therapy. Applicant is Yafei Shanghai Biology Medicine Science & Technology Co., Ltd. Inventors are Liu Chen and Liu Yuan. The patent covers compounds targeting tumor microenvironments with applications in cancer treatment.
What changed
EPO granted patent EP3184540A1 for a tumor microenvironment targeting compound developed for cancer therapy. The compound is designed to specifically target tumor microenvironments, with potential applications in treating tumors (A61P 35/00) as well as ophthalmic conditions (A61P 27/02) and glaucoma (A61P 27/06). Applicant Yafei Shanghai Biology Medicine Science & Technology Co., Ltd. filed multiple IPC classifications covering various pharmaceutical compositions.
Pharmaceutical companies and researchers developing oncology drugs should review this patent to assess potential freedom-to-operate implications. Entities working on tumor-targeting therapeutics should evaluate whether their compounds fall within the scope of these claims. The designated states cover major European markets including DE, FR, GB, IT, ES, NL, BE, and 29 other European countries.
Source document (simplified)
SPECIFICALLY ACTIVATED MICROMOLECULAR TARGET COUPLING BODY IN TUMOR MICROENVIRONMENT AND USE THEREOF
Publication EP3184540A1 Kind: A1 Mar 25, 2026
Applicants
Yafei Shanghai Biology Medicine
Science & Technology Co., Ltd.
Inventors
LIU, Chen, LIU, Yuan
IPC Classifications
A61K 31/4745 20060101AFI20260216BHEP A61K 31/7068 20060101ALI20260216BHEP A61K 31/337 20060101ALI20260216BHEP A61P 35/00 20060101ALI20260216BHEP A61P 27/02 20060101ALI20260216BHEP A61P 27/06 20060101ALI20260216BHEP C07K 5/083 20060101ALI20260216BHEP A61K 47/65 20170101ALI20260216BHEP A61K 47/55 20170101ALI20260216BHEP A61K 31/136 20060101ALI20260216BHEP A61K 31/198 20060101ALI20260216BHEP A61K 31/427 20060101ALI20260216BHEP A61K 31/475 20060101ALI20260216BHEP A61K 31/505 20060101ALI20260216BHEP A61K 31/519 20060101ALI20260216BHEP A61K 31/704 20060101ALI20260216BHEP A61K 31/7048 20060101ALI20260216BHEP A61K 31/7072 20060101ALI20260216BHEP A61K 31/7076 20060101ALI20260216BHEP A61K 47/54 20170101ALI20260216BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Named provisions
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Therapeutics (A61P) publishes new changes.